United States · Health Care · USD (Thousands) · Annual
Reported figures and Equlion model projections for the next 5 years.
Amounts in USD (thousands); stock price per share. Values that are missing or fail Equlion's automated data-quality checks are shown as “-”. Projections are model estimates, not investment advice.
Want the full financial forecast report for Lyra Therapeutics, Inc.? It covers the balance sheet, income statement, cash flow and Equlion model projections.
| Key metrics | Actual | Forecast | ||||
|---|---|---|---|---|---|---|
| Metric | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
| ROE | -184.99% | -3.27% | -1.89% | -4.03% | -4.67% | -5.21% |
|---|---|---|---|---|---|---|
| ROA | -89.43% | -0.55% | -0.3% | -0.61% | -0.65% | -0.67% |
| Gross Margin | 100% | 88.5% | 88.18% | 88.04% | 87.74% | 87.78% |
| Total Assets | $66,346.00K | $68,407.52K | $70,633.96K | $73,038.52K | $75,635.44K | $78,440.12K |
| Net Income | -$93,435.00K | -$372.83K | -$210.06K | -$435.04K | -$482.50K | -$512.90K |